Previous Page  28 / 76 Next Page
Show Menu
Previous Page 28 / 76 Next Page
Page Background


NCCN Policy Initiatives


NCCN Annual Report 2016

2016 Highlights

In 2016, NCCN's Oncology Policy Program team grew

substantially as did its reach among oncology policy

stakeholders. In addition to its annual oncology policy summit

series, NCCN actively served as a voice for patients and

providers, submitting commentary on their behalf to leadership

in Washington, DC, thus enhancing the influence of NCCN.

A Voice for Value in Washington, DC

In 2016, tides changed in Washington, DC with a move toward

a national health care system in which providers are rewarded

for quality care, as opposed to volume-driven fee-for-service


As a result, regulation was proposed that detailed the principles

of these new reimbursement models by Centers for Medicare &

Medicaid Services (CMS) and other regulatory bodies. As part

of its mission to improve the lives of patients with cancer, NCCN

provided a voice on behalf of providers and patients, submitting

commentary on major proposed rules in order to ensure a

national health care system in which patients have fair access

to high-quality, high-value cancer care.

NCCN provided comment on the following rules and quality

measure proposals:

CMS MACRA Proposed Rule

Office of the National Coordinator for Health Information

Technology (ONC) Interoperability for MACRA Request for


CMS 2017 Hospital Outpatient Prospective Payment

System (HOPPS) Proposed Rule

CMS 2017 Medicare Physician Fee Schedule (MPFS)

Proposed Rule

MIPS Final Rule with Comment Period

Avalere Patient Perspective Value Framework

Doctors Caucus – Passage of MACRA and the 21



Cures Act

CMS and National Quality forum Measures Under

Consideration (MUC)

NCQA Draft Oncology Quality Measures

NCCN also co-signed numerous letters in 2016, supporting

clinical trial transparency, women's preventative health services,

and lung cancer early detection.

The NCCN Oncology Policy Program will continue to monitor

actions in Washington, DC and provide valuable insights to

lawmakers to ensure the best possible treatment and outcomes

for patients with cancer.

Forums for Policy Deliberation

As part of its policy summit series, NCCN brought together key

opinion leaders and decision-makers in the oncology space

to discuss some of the most pertinent issues affecting cancer

care in the United States today, including HIT, quality and value

in cancer care, and biosimilars and molecular testing. These

stakeholders represented patients, clinicians, government and

regulatory organizations, patient advocacy groups, pharma-

biotech companies, payers, and providers.

The following policy summits were held in 2016:

Emerging Issues and Opportunities in Health Information


(June 2016)

Developments in Biosimilars and Molecular Testing

(September 2016)

Value Tools for Patients in Cancer Care (Patient Advocacy


(December 2016)

NCCN staff present the NCCN Evidence Blocks


during the 2016

NCCN Patient Advocacy Summit.